[Form 4] Aldeyra Therapeutics, Inc. Insider Trading Activity
Stephen Machatha, Chief Development Officer of Aldeyra Therapeutics (ALDX), reported the sale of 22,073 shares of common stock on 08/11/2025. The disposals were executed to cover tax withholding obligations upon settlement of time-based restricted stock units. The sales produced a weighted average price of $5.1517, with individual trade prices in the range of $5.06 to $5.29. After the reported transactions the reporting person beneficially owned 221,799 shares, which includes 7,101 shares acquired under the company’s Employee Stock Purchase Plan. No derivative securities were reported.
Stephen Machatha, Direttore dello Sviluppo di Aldeyra Therapeutics (ALDX), ha dichiarato la vendita di 22,073 azioni ordinarie in data 08/11/2025. Le cessioni sono state effettuate per coprire gli obblighi di ritenuta fiscale alla liquidazione di unità di azioni vincolate basate sul tempo. Le vendite hanno realizzato un prezzo medio ponderato di $5.1517, con singole transazioni nel range di $5.06 a $5.29. Dopo le operazioni segnalate, la persona interessata deteneva beneficiariamente 221,799 azioni, che comprendono 7,101 azioni acquisite tramite il Piano di Acquisto Azionario per i Dipendenti della società. Non sono stati segnalati strumenti derivati.
Stephen Machatha, Director de Desarrollo de Aldeyra Therapeutics (ALDX), informó la venta de 22,073 acciones ordinarias el 08/11/2025. Las disposiciones se ejecutaron para cubrir obligaciones de retención fiscal al liquidar unidades de acciones restringidas basadas en el tiempo. Las ventas generaron un precio medio ponderado de $5.1517, con precios por operación en el rango de $5.06 a $5.29. Tras las transacciones informadas, la persona informante poseía a título beneficioso 221,799 acciones, que incluyen 7,101 acciones adquiridas mediante el Plan de Compra de Acciones para Empleados de la compañía. No se informaron valores derivados.
Stephen Machatha, Aldeyra Therapeutics (ALDX)의 최고개발책임자는 08/11/2025에 보통주 22,073주를 매각했다고 보고했습니다. 해당 매각은 시간 기반 제한 주식 단위의 정산 시 세금 원천징수 의무를 충당하기 위해 이루어졌습니다. 매도는 가중평균 가격 $5.1517을 기록했으며, 개별 거래 가격은 $5.06에서 $5.29 사이였습니다. 보고된 거래 후 해당 보고인은 회사의 종업원 주식 매수 계획을 통해 취득한 7,101주를 포함해 221,799주를 실질적으로 보유하고 있었습니다. 파생증권은 보고되지 않았습니다.
Stephen Machatha, directeur du développement d'Aldeyra Therapeutics (ALDX), a déclaré la vente de 22,073 actions ordinaires le 08/11/2025. Les cessions ont été réalisées pour couvrir les obligations de retenue à la source lors du règlement d'unités d'actions restreintes basées sur le temps. Les ventes ont dégagé un prix moyen pondéré de $5.1517, avec des prix par transaction allant de $5.06 à $5.29. Après les transactions déclarées, la personne déclarante détenait à titre bénéficiaire 221,799 actions, dont 7,101 actions acquises dans le cadre du plan d'achat d'actions pour les employés de la société. Aucune valeur dérivée n'a été signalée.
Stephen Machatha, Chief Development Officer von Aldeyra Therapeutics (ALDX), meldete den Verkauf von 22,073 Stammaktien am 08/11/2025. Die Veräußerungen erfolgten, um Steuerabzugsverpflichtungen bei der Abwicklung zeitbasierter Restricted Stock Units zu erfüllen. Die Verkäufe erzielten einen gewichteten Durchschnittspreis von $5.1517, mit Einzelhandelspreisen im Bereich von $5.06 bis $5.29. Nach den gemeldeten Transaktionen hielt die meldende Person wirtschaftlich 221,799 Aktien, einschließlich 7,101 Aktien, die im Rahmen des Employee Stock Purchase Plan des Unternehmens erworben wurden. Es wurden keine Derivate gemeldet.
- Sale was for tax withholding upon RSU settlement, explicitly stated in the filing
- Reporting person retains 221,799 shares of common stock, including 7,101 ESPP shares, after the transaction
- Weighted average sale price disclosed ($5.1517) with the reported price range ($5.06 to $5.29), improving transparency
- None.
Insights
TL;DR: Routine tax-related sale of RSU shares; insider retains substantial direct holdings with no derivatives reported.
The filing shows a standard compensation-related sale rather than an open-market diversification event. The disposition of 22,073 shares was explicitly for tax withholding upon RSU settlement, and the reporting person continues to hold 221,799 shares directly, including 7,101 ESPP shares. The absence of derivative transactions reduces complexity for governance review. This is a customary disclosure under Section 16 and does not itself indicate a change in corporate control or governance policy.
TL;DR: Transaction is operationally routine and neutral; sale details provide transparent pricing and share counts for investor records.
The report records a sale conducted at a weighted average price of $5.1517 with trades between $5.06 and $5.29. The reason provided—covering tax withholding for time-based RSUs—is explicitly stated, which clarifies intent and reduces interpretive risk. Post-transaction direct beneficial ownership of 221,799 shares is disclosed, which is useful for modeling potential insider alignment but requires context of total outstanding shares to assess materiality.
Stephen Machatha, Direttore dello Sviluppo di Aldeyra Therapeutics (ALDX), ha dichiarato la vendita di 22,073 azioni ordinarie in data 08/11/2025. Le cessioni sono state effettuate per coprire gli obblighi di ritenuta fiscale alla liquidazione di unità di azioni vincolate basate sul tempo. Le vendite hanno realizzato un prezzo medio ponderato di $5.1517, con singole transazioni nel range di $5.06 a $5.29. Dopo le operazioni segnalate, la persona interessata deteneva beneficiariamente 221,799 azioni, che comprendono 7,101 azioni acquisite tramite il Piano di Acquisto Azionario per i Dipendenti della società. Non sono stati segnalati strumenti derivati.
Stephen Machatha, Director de Desarrollo de Aldeyra Therapeutics (ALDX), informó la venta de 22,073 acciones ordinarias el 08/11/2025. Las disposiciones se ejecutaron para cubrir obligaciones de retención fiscal al liquidar unidades de acciones restringidas basadas en el tiempo. Las ventas generaron un precio medio ponderado de $5.1517, con precios por operación en el rango de $5.06 a $5.29. Tras las transacciones informadas, la persona informante poseía a título beneficioso 221,799 acciones, que incluyen 7,101 acciones adquiridas mediante el Plan de Compra de Acciones para Empleados de la compañía. No se informaron valores derivados.
Stephen Machatha, Aldeyra Therapeutics (ALDX)의 최고개발책임자는 08/11/2025에 보통주 22,073주를 매각했다고 보고했습니다. 해당 매각은 시간 기반 제한 주식 단위의 정산 시 세금 원천징수 의무를 충당하기 위해 이루어졌습니다. 매도는 가중평균 가격 $5.1517을 기록했으며, 개별 거래 가격은 $5.06에서 $5.29 사이였습니다. 보고된 거래 후 해당 보고인은 회사의 종업원 주식 매수 계획을 통해 취득한 7,101주를 포함해 221,799주를 실질적으로 보유하고 있었습니다. 파생증권은 보고되지 않았습니다.
Stephen Machatha, directeur du développement d'Aldeyra Therapeutics (ALDX), a déclaré la vente de 22,073 actions ordinaires le 08/11/2025. Les cessions ont été réalisées pour couvrir les obligations de retenue à la source lors du règlement d'unités d'actions restreintes basées sur le temps. Les ventes ont dégagé un prix moyen pondéré de $5.1517, avec des prix par transaction allant de $5.06 à $5.29. Après les transactions déclarées, la personne déclarante détenait à titre bénéficiaire 221,799 actions, dont 7,101 actions acquises dans le cadre du plan d'achat d'actions pour les employés de la société. Aucune valeur dérivée n'a été signalée.
Stephen Machatha, Chief Development Officer von Aldeyra Therapeutics (ALDX), meldete den Verkauf von 22,073 Stammaktien am 08/11/2025. Die Veräußerungen erfolgten, um Steuerabzugsverpflichtungen bei der Abwicklung zeitbasierter Restricted Stock Units zu erfüllen. Die Verkäufe erzielten einen gewichteten Durchschnittspreis von $5.1517, mit Einzelhandelspreisen im Bereich von $5.06 bis $5.29. Nach den gemeldeten Transaktionen hielt die meldende Person wirtschaftlich 221,799 Aktien, einschließlich 7,101 Aktien, die im Rahmen des Employee Stock Purchase Plan des Unternehmens erworben wurden. Es wurden keine Derivate gemeldet.
FAQ
What did ALDX insider Stephen Machatha do according to the Form 4?
Why were the shares sold by the ALDX reporting person?
At what price were the ALDX shares sold?
How many ALDX shares does the reporting person own after the transaction?
Were any derivative securities reported in this Form 4 for ALDX?
Does the filing state whether the reporting person filed jointly or individually?
